Imerys


Q1 '25: Decline and Uncertainty

29/04/25 -"During Q1 2025, Imerys managed a small organic sales increase, but the overall picture was rather negative. Revenue, profits, and margins all fell sharply year-on-year, mainly due to weaker markets ..."

Pages
54
Language
English
Published on
29/04/25
You may also be interested by these reports :
29/04/25
During Q1 2025, Imerys managed a small organic sales increase, but the overall picture was rather negative. Revenue, profits, and margins all fell ...

29/04/25
We have lowered our estimates to the lower end of the company’s guidance. While we expect the direct impact of US tariffs on CRH to be limited given ...

28/04/25
Holcim’s first-quarter results showed resilience, with flat like-for-like sales and a 2% increase in recurring like-for-like EBIT in line with ...

25/04/25
Saint-Gobain started 2025 with a solid performance, delivering +3.2% sales growth on a reported basis and showing a clear sequential improvement in ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO